 OncLive | Everolimus Plus Octreotide LAR Is Effective in Advanced Neuroendocrine Tumors OncLive Combination therapy with the oral mammalian target of rapamycin (mTOR) inhibitor everolimus and the somatostatin analogue octreotide long-acting repeatable (LAR) increases the median progression-free survival (PFS) in patients with advanced ... |
